Today's Peptide News — September 1, 2026

A team reporting in Nature Biotechnology has demonstrated a single-molecule peptide sequencing approach that sidesteps the sensitivity limits of mass spectrometry by turning each peptide into a DNA record. Using a modified Edman degradation chemistry, the method iteratively cleaves N-terminal amino acids that have been tagged with peptide-specific DNA barcodes, then converts those tags into PCR-amplifiable reporters that are read out on standard high-throughput sequencers.

The result is single-amino-acid resolution across individual molecules, with the practical advantage that the readout rides on the mature, massively parallel infrastructure already built for genomics rather than requiring bespoke instruments.

Why it matters: reliable single-molecule sequencing is one of the missing tools in peptide science, where low-abundance species and post-translational modifications are routinely lost in bulk assays. A DNA-based readout could make it far cheaper to characterize therapeutic peptides, map degradation products, and profile the immunopeptidome. For a PeptideWiki post, the angle is "how do we actually read a peptide, molecule by molecule" — a short explainer contrasting Edman chemistry, mass spectrometry, and this DNA-barcoding trick, aimed at readers who know peptides but not proteomics methods.

A quantitative systematic review in the Journal of Antimicrobial Chemotherapy takes stock of antimicrobial peptides and peptidomimetics as candidate therapies against the ESKAPEE pathogens — the group of multidrug-resistant bacteria responsible for a large share of hospital-acquired infections. Pooling data across many candidates, the authors document broad in vitro potency but also the recurring obstacles that keep these molecules out of the clinic: host-cell toxicity, proteolytic instability, and poor pharmacokinetics.

The review's value is in quantifying the gap between promise and translation, and in flagging which chemical strategies — peptidomimetic backbones, D-amino acid substitutions, targeted delivery — most consistently improve the therapeutic window.

Why it matters: antibiotic resistance keeps climbing while the small-molecule pipeline thins, and AMPs are one of the most-discussed alternatives. A grounded assessment of where they actually stand is useful counterprogramming to the hype. For PeptideWiki, this is a natural "state of the field" post: what an antimicrobial peptide is, why bacteria struggle to resist them, and the honest engineering problems still blocking approval.

A bioRxiv preprint describes a retro-inverso peptide — built from D-amino acids in reversed sequence — that both inhibits the formation of cross-α amyloid fibrils and disperses preformed biofilm biomass in methicillin-resistant Staphylococcus aureus. The retro-inverso design is the interesting move: reversing the sequence and swapping to D-amino acids can preserve the side-chain geometry that drives binding while making the peptide far more resistant to the proteases that normally chew up therapeutic peptides.

By targeting the structural amyloid scaffolding that holds staphylococcal biofilms together, the peptide attacks a vulnerability that conventional antibiotics, which struggle to penetrate biofilms, largely miss.

Why it matters: biofilm-associated MRSA infections are notoriously hard to clear, and anti-amyloid, anti-biofilm strategies are an emerging complement to killing bacteria outright. For PeptideWiki, a short post on retro-inverso peptides works well — explaining the D-amino acid, reversed-sequence trick and why it is such a common tool for making peptides drug-like, using this MRSA work as the concrete example.

The FDA's Pharmacy Compounding Advisory Committee voted to recommend adding six peptides — BPC-157, KPV, TB-500, MOTS-c, semax, and epitalon — to the 503A bulk substances list that compounding pharmacies can legally use, while rejecting a seventh, emideltide. The votes were narrow, with several passing by a single- or two-vote margin and multiple abstentions.

The recommendations came over the objections of FDA career scientists, who said the evidence base was thin: no human safety studies were identified for KPV, TB-500, MOTS-c, or epitalon, and the studies available for the others were small, short in duration, and incomplete in their safety reporting. Importantly, none of these peptides is an FDA-approved drug, none has yet been added to the list, and the committee's recommendations are non-binding — the agency would still need to accept them and go through formal rulemaking before pharmacies could compound the substances for patients.

Why it matters: these are exactly the peptides driving the gray-market "research peptide" boom, and a compounding pathway would move them one step closer to something patients could obtain through a pharmacy rather than online. The tension between demand and the missing safety data is the story. For PeptideWiki, this is a timely reference post on what the 503A list is, what the vote does and does not change, and where each of the six peptides actually stands on evidence.

Results published in Nature Medicine from the ACCESS Phase 2b trial show that aleniglipron, a once-daily oral small-molecule GLP-1 receptor agonist, produced placebo-adjusted body-weight reductions of roughly 8% to 11% across escalating doses over 36 weeks, reaching up to about 12% total in the highest-dose arm. The 230-participant study met its primary endpoint at all doses, and notably showed no clear weight-loss plateau by the end of the double-blind period.

Because aleniglipron is a small molecule rather than an injectable peptide, it can be taken by mouth with or without food and should be far easier to manufacture at scale than peptide drugs like semaglutide.

Why it matters: oral, small-molecule GLP-1 agonists are the next competitive front in obesity treatment, promising to relieve the supply and cost constraints that have dogged the injectable peptides. For PeptideWiki, the useful angle is comparative: how a small-molecule GLP-1 agonist differs from the peptide agonists the audience already knows, and what "peptide versus small molecule" means for potency, dosing, and access.

Altimmune reported positive topline results from its RECLAIM Phase 2 trial testing pemvidutide, a balanced glucagon/GLP-1 dual receptor agonist peptide, in patients with alcohol use disorder. Over 24 weeks, the 2.4 mg dose produced a statistically significant reduction in heavy drinking days versus placebo, and hit registrational secondary endpoints as well: a two-level drop on the WHO risk-drinking-level scale was seen in about 64% of treated patients versus 35% on placebo, with a generally favorable tolerability profile across the roughly 100-patient study.

The trial extends the GLP-1 class well beyond metabolic disease into addiction, building on a growing body of observational and mechanistic hints that incretin agonists blunt reward-driven consumption.

Why it matters: if incretin peptides can reduce problem drinking, it reframes the class as neuropsychiatric as much as metabolic, with a large potential population. For PeptideWiki, a short post on "GLP-1 beyond weight loss" using pemvidutide as the anchor — covering the addiction and reward-pathway rationale — would land well with readers already tracking the class.

A mouse study covered by ScienceDaily found that two widely used zero-calorie sweeteners, sucralose and stevia, altered the gut microbiome, reduced beneficial bacterial metabolites, and changed the activity of genes tied to metabolism and inflammation. Strikingly, some of those changes appeared in later generations that had never consumed the sweeteners themselves, hinting at effects that outlast the exposure.

The findings are preclinical and in animals, so they do not establish harm in people, but they add to a growing literature suggesting "non-nutritive" sweeteners are not metabolically inert.

Why it matters: sweeteners are consumed by billions of people on the assumption they are neutral, and any multigenerational signal — even in mice — is worth watching. It also intersects with the metabolic-health conversation that surrounds the GLP-1 drugs.

Researchers at the University at Buffalo have developed an injectable hydrogel that turns from a liquid into a smooth, lubricating semisolid depot at body temperature, then sits in an arthritic joint for weeks while gradually releasing drug-loaded nanocarriers. Beyond sustaining the drug locally, the material improves joint lubrication, addressing two problems at once with a single minimally invasive injection.

The approach could let disease-modifying osteoarthritis drugs act where they are needed while limiting systemic exposure, a persistent challenge for a disease with few effective long-term treatments.

Why it matters: osteoarthritis affects hundreds of millions of people and lacks disease-modifying therapy, so a delivery system that keeps drugs in the joint could meaningfully change how candidates are tested and used.

A study in JAMA Network Open, summarized by ScienceDaily, found that a simple waist-circumference measurement — alone or combined with BMI — was about as effective at detecting unhealthy body fat as a newer, more complicated method relying on multiple body measurements. The researchers, at Rutgers Health, also found that BMI by itself missed many people who did carry excess fat, particularly around the waist.

The upshot is that abdominal fat may signal cardiometabolic risk that the number on the scale, and BMI, can obscure.

Why it matters: BMI is the default screening tool everywhere despite well-known blind spots, and evidence that a tape measure adds real information is directly actionable in ordinary clinical practice.